Frontiers in Cardiovascular Medicine · Nov 16, 2026

Cardioprotective Interventions During Anthracycline-Based Chemotherapy: A Systematic Review and Network Meta-Analysis

By Linxuan Luo, Huan Wu, Yi Xiang et al.

Objective: To evaluate efficacy signals of cardioprotective interventions in adults receiving anthracycline-based chemotherapy and assess the certainty and clinical interpretability of the evidence. Methods: PubMed, the Cochrane Library, Web of Science, and Embase were searched from inception through October 22, 2026, for randomized controlled trials. Bayesian random-effects analyses evaluated final left ventricular ejection fraction (LVEF), change in LVEF, definition-specific cardiotoxicity, global longitudinal strain (GLS) change, and natriuretic peptide changes. BNP and NT-proBNP were analyzed separately. Risk of bias, confidence in the evidence, and sensitivity to study exclusion and treatment classification were assessed. Results: Fifty-eight reports representing 59 independent trials were included. Compared with Control, final LVEF was higher with spironolactone (mean difference [MD] 12.08 percentage points, 95% credible interval [CrI] 3.57–20.65) and enalapril (MD 6.64, 95% CrI 0.57–12.80). Lower odds of LVEF-defined cardiotoxicity were estimated for atorvastatin, enalapril, and a cardioprotective diet intervention. In the supplementary pairwise analysis, dexrazoxane was associated with lower odds of composite cardiac events (odds ratio 0.31, 95% CrI 0.16–0.59), although its prediction interval included the null. All treatment-versus-Control CrIs included zero for changes in LVEF, GLS, BNP, and NT-proBNP. Important estimates were sensitive to individual trials or sample-size restrictions. Overall confidence was very low for network comparisons with completed ratings; certainty for the dexrazoxane composite-event comparison was low. Conclusion: Selected interventions showed outcome-specific efficacy signals, but sparse evidence, uncertainty, and limited robustness precluded a reliable treatment hierarchy. These findings identify priorities for further randomized trials rather than establish comparative recommendations for clinical drug selection. Comparative safety and net clinical benefit remain undetermined.

The paperJournal siteInterventions

AgingResearch.News